drugset / Trial / NCT02609139
Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects
RandomizedCrossoverOpen-labelBasic science
Summary
This is a Phase 1, open-label, single-dose, within-cohort randomized, 2-way crossover study to evaluate the PK of orally administered PF-06650833 modified release tablets under fasted and high fat meal fed conditions in healthy subjects.
Timeline
- Start
- 2015-11
- Primary completion
- 2016-02
- Completion
- 2016-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZIMLOVISERTIB | Small molecule | 20 mg | Oral |
| Subject | ZIMLOVISERTIB | Small molecule | 100 mg | Oral |
| Subject | ZIMLOVISERTIB | Small molecule | 400 mg | Oral |
Indications
No indication recorded.